Key result
Vericiguat cuts cardiovascular death or heart failure hospitalization versus placebo in HFrEF.
Why the study?
Despite advances in pharmacological treatments for HFrEF, up to 10% of patients progress to advanced stages with high mortality and hospitalization rates, necessitating new therapies.
Does vericiguat reduce the composite of cardiovascular death or first heart failure hospitalization in patients with HFrEF who had recently been hospitalized or received intravenous diuretic therapy?
Does vericiguat reduce the composite of cardiovascular death or first heart failure hospitalization in patients with HFrEF who had recently been hospitalized or received intravenous diuretic therapy?
Vericiguat is an effective therapy for reducing cardiovascular death and heart failure hospitalizations in high-risk HFrEF patients with recent worsening events, potentially reducing healthcare costs.
May support vericiguat in advanced HFrEF; hypothesis-generating and requires RCT validation.
The introduction of multiple new pharmacological agents over the past three decades in the field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of mortality and hospitalizations, and consequently, the prevalence of HFrEF has increased, and up to 10% of patients progress to more advanced stages, characterized by high rates of mortality and hospitalizations and poor quality of life. Vericiguat, a novel oral soluble guanylate cyclase stimulator, has proved effective in patients with HFrEF who had recently been hospitalized or had received intravenous diuretic therapy. In these patients, vericiguat reduced the primary outcome of death from cardiovascular causes or first hospitalization for heart failure in comparison with placebo. By reducing hospital admissions in a population at a very high risk of re-hospitalization, vericiguat might have a positive impact on healthcare costs for the management of HFrEF.
No takes yet. Share an insight, caveat, or question.
Caminiti et al. (2023) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Vericiguat vs. Placebo was evaluated on Death from cardiovascular causes or first hospitalization for heart failure. Vericiguat reduced death from cardiovascular causes or first hospitalization for heart failure compared with placebo in patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: